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Abstract 
Chemokines mediate leucocyte migration and 
homeostasis, and are key targets in inflammatory 
diseases including atherosclerosis, cytokine 
storm and chronic auto-immune disease. 
Chemokine redundancy and ensuing network 
robustness has frustrated therapeutic 
development. Salivary evasins from ticks bind 
multiple chemokines overcoming redundancy, 
and are effective in several pre-clinical disease 
models. Their clinical development has not 
progressed due to concerns regarding potential 
immunogenicity, parenteral delivery and cost. 
Peptides mimicking protein activity can 
overcome the perceived limitations of therapeutic 
proteins. Here we show that peptides possessing 
multiple-chemokine-binding and anti-
inflammatory activities can be developed from 
the chemokine-binding site of an evasin. We used 
hydrogen–deuterium exchange mass 
spectrometry to map the binding interface of the 
evasin P672 that physically interacts with C-C 
motif chemokine ligand 8 (CCL8) and 
synthesized a 16-mer peptide (BK1.1) based on 
this interface region in evasin P672. Fluorescent 
polarization and native mass spectrometry 
approaches showed that BK1.1 binds CCL8, 
CCL7 and CCL18, and disrupts CCL8 
homodimerization. We show that a BK1.1 
derivative, BK1.3, has substantially improved 
ability to disrupt P672 binding to CCL8, CCL2 
and CCL3 in an AlphaScreen assay. Using 
isothermal titration calorimetry, we show that 
BK1.3 directly binds CCL8. BK1.3 also has 
substantially improved ability to inhibit CCL8, 
CCL7, CCL2 and CCL3 chemotactic function in 
vitro. We show that local as well as systemic 
administration of BK1.3 potently blocks 
inflammation in vivo. Identification and 
characterization of the chemokine-binding 
interface of evasins could thus inspire the 
development of novel anti-inflammatory peptides 
that therapeutically target the chemokine network 
in inflammatory diseases.  
 
The disease burden created by inflammation 
ranges from acute multi-organ failure in influenza 
or coronavirus COVID19-induced cytokine 
storm (1-3), to chronic autoimmune diseases such 
as rheumatoid arthritis, and to inflammatory 
diseases such as atherosclerosis (4). Chemo-
attractant cytokines or chemokines are key 
players in cytokine storm hyperinflammation 
syndromes (1-3,5), in diverse autoimmune 
diseases (6), and in atherosclerosis (7). 
Chemokines are classified as CCL, CXCL, 
CX3CL or XCL based on the spacing of their N-
terminal cysteine residues (8). The binding of 
chemokines to G-protein coupled receptors 
expressed on leucocytes causes their directed 
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migration to sites of inflammation, and also 
maintains leucocyte homeostasis (8). Although 
chemokines are promising therapeutic targets, 
clinical trials of agents that target single 
chemokine ligands or receptors have not been 
successful (9,10). The reason for this is thought, 
at least in part, to lie in the apparent redundancy 
within the chemokine network which creates 
robustness (11). Natural selection in diverse 
pathogens including viruses (12), helminths (13), 
and ticks (14) has resulted in the convergent 
evolution of structurally unrelated proteins that 
bind multiple chemokines. This phenomenon 
suggests that ability to target multiple 
chemokines is an effective strategy to disable the 
chemokine network and host defense 
mechanisms such as inflammation. The 
application of such chemokine-binding proteins 
in diverse pre-clinical models of inflammation 
has been well documented (15,16). Of particular 
interest in the development of therapeutics that 
target chemokines are the evasin proteins from 
ticks. Three of these proteins were initially 
identified in seminal studies from the Proudfoot 
laboratory (reviewed in (16)), and we and others 
have since identified and characterized over 40 
evasins to date (17-21). Evasins fall into two 
classes, A, exclusively binding CCL chemokines, 
and B, exclusively binding CXCL chemokines 
(reviewed in (14)). When administered 
parenterally, evasins have potent anti-
inflammatory efficacy in pre-clinical disease 
models including myocardial ischemia and 
reperfusion injury, intestinal ischemia, colitis, 
acute pancreatitis, lung inflammation, arthritis, 
psoriasis and graft-versus-host disease (reviewed 
in (16)). Unfortunately, the clinical translation of 
evasins has not progressed, in part due to the 
perceived limitations of using foreign proteins as 
biological therapeutics such as immunogenicity, 
requirement for parenteral delivery, and 
relatively high manufacturing costs (22,23). 
Peptidomimetic and peptide therapeutics 
developed from foreign proteins and mimicking 
their activity can overcome some of these 
limitations (24), and creating such agents from 
evasins is the driver of this work. 
 
We have recently shown that a class A evasin 
EVA-P672 (here referred to as P672), identified 
from the tick Rhipicephalus pulchellus, binds 
several CC-class chemokines, and contains a 
CCL8 binding region in its N-terminus (20). Here 
we report the experimental mapping of the 
P672:CCL8 interface using hydrogen deuterium 
exchange mass spectrometry and biophysical 
analyses and identify a linear sequence in the N-
terminus of P672 that binds CCL8. Using this 
information, we designed a series of short 
synthetic peptides which demonstrate 
promiscuous chemokine binding and 
neutralization activity in vitro. One of these 
peptides, BK1.3 was shown to be able to block 
inflammatory recruitment of neutrophils, 
eosinophils, monocytes and T-cells in an in vivo 
air-pouch model, induced by the pathogen-
associated molecular pattern (PAMP), zymosan. 
Taken together, these experiments provide proof-
of-concept that small biologically active peptides 
that target multiple chemokines and have anti-
inflammatory activity can be engineered through 
the analysis of evasin:chemokine interactions.  
 
Results 
Hydrogen/deuterium exchange mass 
spectrometry reveals the P672:CCL8 complex 
interface 
We performed peptide-resolution 
hydrogen/deuterium exchange mass 
spectrometry (HDX-MS) to characterize the 
interaction between P672 and CCL8. HDX-MS 
measures the rate of exchange of protein 
backbone hydrogen atoms with deuterium atoms 
in the solvent (25). Changes in deuterium uptake 
between free and complexed proteins can inform 
on protein-protein interfaces and conformational 
dynamics (26). Regions that are protected from 
deuterium uptake upon complex formation are 
shielded from the solvent typically due to 
involvement in inter-protein hydrogen-bonding 
networks that stabilize the complex (27). We 
measured the deuterium uptake of free P672, free 
CCL8 and of each protein upon complex 
formation. After confirming satisfactory 
sequence mapping and coverage of each protein 
(100% for P672, 96.9% for CCL8, Fig. S1), we 
compared the deuterium uptake of the free 
species with that of the P672:CCL8 complex 
species (5 s, 30 s, 5 min and 60 min incubation 
time points, Fig. S2). The results were mapped on 
to a homology model of the P672:CCL8 complex 
(Fig. 1A, B). While a large part of P672 and CCL8 
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showed no significant changes in H/D exchange 
rates, we observed significant decrease in H/D 
exchange in R18-S27 of CCL8 (% relative 
deuterium uptake (%D) ranging from -6 to -18) 
which lies in the N-terminal extended loop/b1-
region (28), and in the N-terminal unstructured 
(predicted) region of P672 (E22-F32, D% up to -
58%), indicating protection of these regions from 
solvent exposure when in complex (Fig. 1B-D, 
Fig. S2). All residues in CCL8 and most in P672 
(F25-C30, F32) from these regions were 
protected at all time points (Fig. S2). Spectra of 
two representative P672 peptides showing a 
reduction in deuterium incorporation for this 
protected region upon complex formation are 
shown in Fig. 1E. An increase in relative 
deuterium uptake was observed for the C-
terminal region of P672 (G87-C94, %D ranging 
from 15 to 18%), indicating higher exposure to 
solvent water after complex formation (Fig. 1C 
and Fig. S2). All HDX-MS uptake data and plots 
are shown in Table S1. These results indicate that 
the P672 (E22-F32) and CCL8 (R18-S27) regions 
are likely involved in P672:CCL8 complex 
formation. The protected regions of P672 and 
CCL8 overlap the binding interface predicted by 
the homology model of P672:CCL8 (20) 
suggesting that these residues are involved in 
protein-protein interactions. Changes in the 
deuterium uptake in these regions show little 
time-dependent change (5s - 60 min, Fig S2), in 
agreement with the tight-binding kinetics of 
P672:CCL8 interaction (Kd = 8.5 nM, residency 
time = 27 min) (20).  
 
Residues E22-F32 in P672 contain a 
transferable CCL8 binding activity 
To explore the function of P672 (E22-F32) we 
swapped this region with the corresponding 
segment of EVA1, which is a related CC-
chemokine binding evasin that does not bind 
CCL8 (20) (Fig. 2A). We analysed the CCL8 
binding activity of the resulting hybrid protein 
EVA1(P67222-32) (Fig. 2B) using biolayer 
interferometry (BLI), and found that it bound 
CCL8, whereas, consistent with previously 
reported results (20), the parental evasin EVA1 
did not. Dose - titration experiments indicated 
that EVA1(P67222-32) bound CCL8 with modest 
affinity, Kd = 490 nM. Taken together with the 
HDX-MS analysis, these experiments confirmed 
that P672(E22-F32) is involved in forming 
protein-protein interactions with CCL8, and that 
this function can be transferred to another evasin. 
 
Development of BK1.1, a CCL8 binding peptide 
Guided by the HDX-MS and swapping 
experiments we tested a number of tiled peptide 
fragments spanning the E17-F32 region in P672 
for CCL8 binding (Fig. 3A). Y21 and the four 
acidic residues N-terminal to Y21, were also 
included in this array, as both P672 and EVA1 
share this region. To prevent disulfide bond 
formation, all peptides were synthesized with 
Cys30 replaced by Ala. These peptides were 
synthesized with N-terminal fluorescein 
isothiocyanate (FITC) to assess their chemokine 
binding affinities using a fluorescence 
polarization assay (BK1-6, Fig. 3B). The longest 
test peptide P672(E17-F32) was termed 
BK1.1FITC, and a corresponding scrambled 
sequence was generated as a negative control 
(SCRFITC). Only the full contiguous peptide 
(BK1.1FITC, displayed an increase in anisotropy 
upon incubation with CCL8 (at a concentration of 
1 µM) compared to control, indicating a binding 
interaction. Interestingly, no changes in 
anisotropy was observed for Y21-F32 (BK6FITC) 
under the conditions tested. We next used 
fluorescent polarization and dose-titration of 
CCL8 to estimate its affinity for BK1.1FITC (Fig. 
3C), and found that this was relatively high (Kd 
=156 ± 7 nM (mean, ± s.e.m.). To further explore 
the mechanism of BK1.1 binding, we performed 
alanine-scanning mutagenesis where each residue 
of BK1.1FITC was replaced with Ala. We tested 
each mutant for binding to CCL8 using the 
fluorescent anisotropy assay to measure binding 
affinity. This revealed a number of key residues 
that contribute to CCL8 binding (Fig. 3D, Table 
S2). Significant differences were observed when 
aromatic residues Tyr and Phe (Tyr21, Tyr31, 
Phe25 and Phe32) were mutated. The Asp18 
mutation also showed reduced affinity, 
supporting the peptide tiling data and indicating 
the importance of interactions outside of the Y21-
F32 region. Notably, mutation of Pro27 
completely abolished binding to CCL8 indicating 
that it has a key function. 
 
BK1.1 disrupts CCL8 homodimerization 
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To further investigate the binding of BK1.1 to 
CCL8 we employed native mass spectrometry. 
Under native conditions, CCL8 exists as a 
homodimer (Fig. 3E). However, after incubation 
with BK1.1, both 1:1 and 2:1 species of the 
BK1.1:CCL8 complex were observed, together 
with CCL8 monomer and BK1.1. The presence of 
CCL8 monomer and BK1.1 species is likely due 
to partial dissociation of the complex. The 
stoichiometry observed was supported by 
dissociation of these complexes using higher-
energy collisional dissociation (HCD). BK1.1 
can thus form a stable 1:1 complex with CCL8 
and disrupt CCL8 homodimerization in line with 
our P672:CCL8 native mass spectrometry 
analysis (20). Interestingly, the presence of low 
levels of 2:1 BK1.1:CCL8 complex indicate a 
possible second site of BK1.1 binding.  
 
BK1.1 promiscuously binds three CC class 
chemokines 
We next screened BK1.1FITC for binding against 
the 13 CC-chemokines known to bind to P672 
(20) (Fig 3F). CCL7, CCL8 and CCL18 caused 
significant increase in anisotropy of the emitted 
light compared to the negative control CXCL1, a 
chemokine that does not bind P672 (20) 
suggesting a binding interaction between 
BK1.1FITC and these chemokines. Fluorescent 
polarization displacement assays with unlabeled 
BK1.1 confirmed its binding to CCL7, CCL8 and 
CCL18 (Fig. 3G-I). 
 
Engineering of peptides with improved potency 
and promiscuous CC-chemokine binding 
We next explored the role of the four acidic 
residues N-terminal to Y21, and the impact of 
Cys-Ala mutation introduced in BK1.1. We 
designed two shorter peptides from P672 residues 
Y21-F32, with either Ala (peptide Y21F32, 
C30A) or Cys (peptide Y21F32) at position 30 
(Fig. 4A), and compared them to BK1.1 in their 
ability to disrupt the interaction between P672 
and CCL8 using an AlphaScreen assay. We found 
that all three peptides significantly disrupted the 
interaction, with the effect of Y21F32, and BK1.1 
far exceeding that of peptide Y21F32, C30A (Fig. 
4B). We found that only Y21F32 and BK1.1 
disrupted the P672 - CCL2 interaction, and that 
only Y21F32 disrupted the P672 – CCL3 
interaction (Fig. 4C and D). These results implied 
that the four acidic residues N-terminal to Y21, 
and the Cys residue were important for 
chemokine binding. To improve chemokine 
binding affinity, we designed a series of peptides 
(BK1.2-BK1.5) based on BK1.1 (Fig. 4A), where 
we maintained the four acidic residues N-terminal 
to Y21, and also Cys at position 30. As 
cyclisation is known to improve conformational 
stability, a cyclic version BK1.2 was designed, 
with Cys30 cyclized to a N-terminal Tyr residue 
that was introduced (29,30). As a control we also 
created a non-cyclized version of this peptide, 
BK1.3. We assayed the binding of these peptides 
to CCL8 by examining their ability to disrupt the 
P672:CCL8 interaction using an AlphaScreen 
assay (Fig. 4E and F). We found that both BK1.2 
(IC50 = 729 nM) and BK1.3 (IC50 = 238 nM) had 
significantly improved ability to disrupt the 
P672:CCL8 interaction in comparison to BK1.1 
(IC50 = 59.1 µM). To explore the mechanism of 
enhanced activity we created further peptides 
BK1.4 (cyclized) and BK1.5 (linear) that lacked 
the N-terminal Tyr. BK1.4 is cyclized to Cys30 
through the N-terminal Glu17 residue. We found 
that these modifications resulted in a significant 
reduction of binding activity in comparison to 
BK1.3 (Fig. 4E and F). These results suggested 
that cyclisation itself is not critical but instead 
that the N-terminal Tyr is important. Examination 
of the peptides by MS revealed that BK1.3 readily 
oxidized to form a disulfide-bonded dimer, 
whereas BK1.5 was monomeric (Fig. S3). To 
examine the binding profile of BK1 derivatives 
for other CC-chemokines, we tested their ability 
to inhibit P672 interactions with CCL2 and CCL3 
using AlphaScreen (Fig. 4G-J). While BK1.1 did 
not inhibit, in line with the lack of binding 
observed against CCL2 and CCL3 in fluorescent 
polarization assays (Fig. 3F), all other BK 
derivatives showed good inhibition against 
CCL2, and weaker inhibition against CCL3. The 
IC50 of BK1.3 against CCL2 was 5.7 µM and 
against CCL3 was 43 µM. Isothermal titration 
calorimetry (ITC) (31) confirmed direct binding 
of BK1.3 to CCL8 (Kd = 217 nM, stoichiometry 
= 0.78, Fig. 4K and L).  
 
Engineered peptides promiscuously neutralize 
chemokine function 
We next explored the effect of BK1.1, 1.2 and 1.3 
on CCL8, CCL7, CCL3 and CCL2 induced cell 
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migration. These chemokines were chosen as 
P672 has previously been shown to neutralize 
them in analogous experiments (20). We used the 
acute monocytic leukemia cell line THP-1 (32) in 
these studies as they express CCR1, CCR2 and 
CCR5 (33,34). All three receptors are activated 
by CCL8, CCL7 and CCL2, while CCL3 
activates CCR1 and CCR5 (35). We performed 
these experiments with a single concentration of 
peptide (10 µM, Fig. 5A-D). P672 (300 nM) was 
included as a positive control, and a scrambled 
version of BK1.1 (SCR) as a negative control. We 
observed that BK1.1 reduced CCL8-induced 
migration to background levels, and had a 
modest, but significant effect on CCL7-induced 
migration, consistent with its ability to bind these 
chemokines in the fluorescent polarization assay 
(Fig. 5A and B). There was no significant effect 
on CCL3 induced migration (Fig. 5C). However, 
we found that it had a modest but significant 
effect in inhibiting CCL2 induced cell migration 
(Fig. 5D). Like BK1.1, BK1.2 and 1.3 also 
reduced CCL8 induced cell migration to baseline 
levels, and had a stronger effect on CCL7 and 
CCL2-induced migration (Fig. 5A, B and D). 
However, unlike BK1.1 they also significantly 
reduced CCL3 induced cell migration (Fig. 5C). 
We next performed dose titration experiments to 
establish the relative potencies (IC50) of the 
engineered peptides against CCL8 (Fig. 5E and 
F). We found that BK1.1, BK1.2 and BK1.3 had 
IC50 values for CCL8 inhibition of 458 nM, 19 
nM and 6.7 nM respectively, correlating well with 
the increased binding affinity. In comparison, the 
positive control, P672 had an IC50 of 2.6 nM. 
Taken together, these results indicated that the 
engineered peptides promiscuously neutralize 
different CC class chemokines, with BK1.3 
possessing the most potent activity.  
 
Engineered peptides prevent cellular chemokine 
binding 
To explore the effect of BK1.1 and derivatives on 
chemokine ligand – cell interactions we 
developed a fluorescent-chemokine cell binding 
assay. Fluorescent chemokine (conjugated to 
AlexaFluor-647) binding to THP-1 cells results in 
an increase in the cellular fluorescence intensity, 
which is quantitatively measured using flow 
cytometry. In dose-response assays, we found 
that increasing doses of peptide would suppress 
CCL8-647 and CCL2-647 induced cellular 
fluorescence (Fig. 5G-J). IC50 values for BK1.1, 
BK1.2 and BK1.3 against CCL8-647 were found 
to be 5.8 µM, 630 nM and 47 nM respectively, 
while P672 had an IC50 of 21 nM (Fig. 5G and H). 
In similar assays IC50 values for BK1.1, BK1.2 
and BK1.3 against CCL2-647 were found to be 
45 µM, 6.3 µM and 2.2 µM respectively, while 
P672 had an IC50 of 21 nM (Fig. 5I and J). Taken 
together, these results indicate that the engineered 
peptides not only bind chemokines 
promiscuously, but neutralize their chemotactic 
function by preventing them from binding to 
cells.  
 
Engineered peptide BK1.3 has in vivo anti-
inflammatory activity 
The above results suggested that the chemokine-
neutralizing properties of the engineered peptides 
may translate into anti-inflammatory activity in 
vivo. To study this, we tested the lead peptide 
BK1.3 in a mouse short-term inflammation 
model. In this model, zymosan, a yeast cell wall 
derived PAMP, activates cytokine and 
chemokine production, and leucocyte infiltration, 
when injected into an artificially created 
subcutaneous air-pouch (36,37). Characterization 
of this model showed that Ccl9 is expressed at a 
high basal level but is not induced by zymosan. 
Ccl2, 5, 11, 12, 20, 22, 24, and Cxcl1, 2, 4, 5, 11, 
13, 16 are expressed (>3 fold) at 4 hours 
following zymosan, and Ccl2, 5, 12, and Cxcl2, 
4, 13, 16 are expressed (>3 fold) at 24 hours (Fig. 
S4). We injected BK1.3 and control SCR 
peptides, and the positive control P672 directly 
into the air-pouch at 0 and 9 h following zymosan 
injection. We characterized the air-pouch exudate 
using flow cytometry at 24 hours after zymosan 
injection to assess the severity and nature of 
inflammation. Both BK1.3 and P672 showed a 
strong and significant reduction in the number of 
neutrophils, eosinophils, monocytes and T-cells 
recruited to the air-pouch (Fig. 6A-F). We next 
determined if systemic administration of BK1.3 
peptide would have anti-inflammatory activity. 
We injected BK1.3 and control SCR peptides, 
and the positive control P672 intra-peritoneally at 
0 and 9 h following zymosan injection, and 
characterized the air-pouch exudate at 24 hours 
after zymosan injection as before. Again, both 
BK1.3 and P672 showed a substantial and 
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significant reduction in the number of 
neutrophils, eosinophils, monocytes and T-cells 
recruited to the air-pouch (Fig. 6G-L). These 
results show that the engineered peptide BK1.3 
has in vivo local and systemic anti-inflammatory 
activity. 
 
Discussion 
Efforts to develop peptide or peptidomimetic 
agents that bind and inhibit multiple chemokines 
have to date been based on the sequences of 
chemokine-binding regions of receptors (38-40), 
and the unbiased identification by phage display 
of peptides that bind anti-receptor antibodies 
(41). These approaches have resulted in the 
identification of peptides that, where reported, 
bind one or more chemokines with relatively low 
(micromolar - millimolar) affinity. Individual 
peptides designed from the CCL5 heterodimer 
interface have been developed that efficiently 
disrupt heterodimerization of CCL5 with CCL17, 
CXCL4 and CXCL12, but are however specific 
for the heterodimer pair (42), and lack ability to 
target chemokines promiscuously. We have 
developed an alternative approach, which starts 
with the identification of promiscuous 
chemokine-binding proteins that have evolved in 
parasitic organisms to evade the host chemokine 
network. We followed these initial discoveries by 
mapping the chemokine-binding segment of one 
of these proteins, and then designing small 
peptides based on the mapped segment that not 
only promiscuously bind chemokines with 
relatively high (nanomolar) affinity but also have 
anti-inflammatory activity in vivo.  
 
In this study we used HDX-MS and identified a 
11-residue region (E22-F32) of P672 that was 
protected from deuterium uptake upon 
complexing with CCL8. Swapping this region 
into EVA1, an evasin that does not bind CCL8, 
transferred CCL8 binding activity to the hybrid 
protein. These results indicate that this 11-residue 
region binds CCL8. While the structural 
modelling informed the potential protein-protein 
interaction interface, the HDX-MS provided 
experimental validation and confidence which 
accelerated the discovery process. The HDX-MS 
result also indicated that CCL8 residues R18-
S27, which overlap the N-terminal loop (C12-
R24) (28), interact with P672. A key function of 
the N-terminal loop of CC chemokines is receptor 
binding, and it is targeted by several pathogenic 
chemokine-binding proteins (43). For example, 
the viral chemokine binding protein VV-35kDa 
targets K19 and R24 of CCL2 (44) and the viral 
chemokine binding protein vCCI targets R18 and 
R24 of CCL2 (45). This common mechanism 
suggests the convergent evolution of these 
proteins to target the residues found in this region. 
The binding of P672 to this region would 
competitively prevent CCL8 binding to its 
receptor, explaining how CCL8 function is 
neutralized. The N-terminal loop of CCL8 and 
other CC chemokines is also part of the 
homodimerization interface (28,43), and binding 
to this loop explains the prevention of CCL8 
dimerization by P672 reported previously (20).  
 
To develop chemokine-binding peptides based on 
the 11-residue segment identified by HDX-MS 
we initially screened a tiled array covering this 
segment. We found that addition of four acidic N-
terminal residues and Tyr21 was necessary to be 
able to detect binding under these conditions, 
suggesting these acidic residues may be needed 
for increased affinity, or that the shorter peptides 
were sterically hindered from binding by the 
FITC moiety. Alanine scanning mutagenesis of 
the 16-residue peptide BK1.1 indicated that 
binding to CCL8 was mediated by Tyr and Phe 
residues, and also by the acidic residues at the N-
terminus. Notably, Tyr and Phe are both found in 
protein interaction “hot-spots” (46,47), and 
complementarity in surface charge mediated by 
acidic residues can modulate protein interactions 
(48,49). A notable finding was that the Pro 
residue is critical for binding. Pro residues are 
found in turns (50), and can undergo cis-trans 
isomerization (51), making it likely that the Pro 
residue is of structural importance for BK1.1. We 
observed that BK1.1 prevents CCL8 
homodimerization, suggesting that it likely 
employs a similar mechanism as P672 in binding 
CCL8, i.e. to the N-loop region. The fluorescent 
polarization studies reported indicate that BK1.1 
also binds the chemokines CCL7 and CCL18, but 
not several others. The molecular mechanism of 
promiscuous chemokine binding by this short 
peptide is unclear at present and will require 
structural approaches for a more complete 
understanding. 
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Given the role of Pro in protein conformation, we 
decided to employ cyclisation as a strategy for 
restricting conformational flexibility. A 
surprising finding was that the addition of an N-
terminal Tyr residue led to enhanced potency. 
This finding may be explained by the observation 
that Tyr residues are found in protein interaction 
“hot-spots” (46), and indeed Tyr and sulfoTyr are 
used by chemokine receptors to target the 
chemokine N-loop region (52). The role of the re-
introduced Cys30 is supported by BK1.5, which 
differs by a single residue in comparison to 
BK1.1, and has marked improvement in affinity. 
The substantial enhancement of activity of BK1.3 
thus likely arises from addition of Tyr and re-
introduction of Cys30. In addition, it is likely that 
the unpredicted formation of a Cys linked dimer 
in BK1.3 enhances the functional affinity or 
avidity of the molecule. The isothermal 
calorimetry experiment assessing binding of 
BK1.3 to CCL8 indicated an unusual 
stoichiometry (n = 0.78). BK1. 3 is a dimer, with 
two presumed CCL8 binding sites, and after the 
first binding event we assume that the second site 
might be partially sterically hindered and not 
effectively bind to a second molecule of CCL8. 
This could explain how the estimated 
BK1.3:CCL8 stoichiometry (n=0.78) lies 
between 1:1 (n = 1) and 2:1 (n = 0.5). 
 
Peptide cyclisation did not appear to enhance 
affinity, as evidenced by the lack of improvement 
of BK1.4 in comparison to BK1.5 or BK1.2 in 
comparison to BK1.3. This may be, in part, due 
to non-optimized cyclisation points and/or forced 
constraint. The serendipitous discoveries 
reported here - addition of N-terminal Tyr, and 
the dimerization consequent to the presence of an 
unpaired Cys residue - may be exploited in the 
rational design of other chemokine N-loop-
binding peptides.  
 
The improvement in binding to CCL8 observed 
in the BK1.1 – BK1.3 peptide series, as well as 
their ability to inhibit P672:CC-chemokine 
interactions (CCL8, CCL2, CCL3), correlated 
with increased chemokine neutralization potency 
and promiscuity. In cell-based chemotaxis assays 
we found that the improvement in binding 
affinity for CCL8 translated into increased 
potency for inhibiting CCL8-induced cell 
migration, as evidenced by the reduced IC50. In 
addition to neutralizing CCL8 and CCL7, which 
was predicted by the BK1.1 fluorescent 
polarization binding study, the peptides BK1.2 
and BK1.3 were also able to neutralize CCL2 and 
CCL3 induced chemotaxis. The inhibition of 
chemokine binding to cells indicate that the 
mechanism of neutralization is the prevention of 
chemokine binding to the cells, likely by 
preventing chemokine-receptor interactions.  
 
A critical step in the clinical translation of novel 
anti-inflammatory therapeutics is the 
demonstration of efficacy in vivo, using a model 
where many components of the immune-
inflammatory network are activated. We used a 
short-term inflammation model using the well 
characterized PAMP, zymosan, which activates 
TLR2 signaling (53), and results in the 
production of cytokines, chemokines, and 
complement (36,37). Our data indicate that 
zymosan-induced inflammation is significantly 
inhibited by both local as well as systemic 
administration of BK1.3. It is likely that the in 
vivo mechanism of action of BK1.3 includes the 
inhibition of CC-class chemokines which not 
only are chemoattractants for leucocyte 
recruitment, but also heterodimerize and 
synergize with certain CXC-class chemokines 
(42).  
 
In conclusion, we have elucidated the molecular 
mechanism for the interaction between the tick 
salivary protein P672 and a target chemokine, 
CCL8, and have used the information to design 
promiscuous CC-chemokine binding peptides 
that bind with high affinity, neutralize chemokine 
action by preventing receptor binding and have 
anti-inflammatory activity in vivo. Our work 
indicates that peptides with promiscuous 
chemokine-binding and anti-inflammatory 
activity can be developed by studying 
evasin:chemokine interactions. Such peptides 
could provide a route to the development of new 
anti-inflammatory therapeutics that have 
relevance to not only chronic diseases such as 
atherosclerosis and rheumatoid arthritis, but also 
to acute illnesses such as influenza or COVID19-
induced cytokine storm. 
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Experimental procedures 
Reagents 
All chemokines, unless otherwise stated, were 
purchased from Peprotech (UK). Fluorescent 
chemokines were purchased from Almac (UK). 
THP-1 cells (ECACC 88081201) were 
maintained in RPMI-1640 media supplemented 
with 10% fetal calf serum and 4 mM L-glutamine. 
Cultures were maintained between 3×105 and 
1×106 cells/ml in a 37oC incubator with 5% CO2. 
HEK 293F cells (Thermo Fisher) were 
maintained between 3×105 and 1×106 cells/ml in 
a 37oC incubator with 8% CO2 and 130 RPM 
agitation in FreeStyle™ 293 Expression Medium.  
 
Plasmids 
Evasins were cloned in the expression vector 
pHLSec (54). P672 (N-terminal 8xHis-StrepII 
tag) expression vector and EVA1 (C-terminal 
Strep-8xHisII tag) have been described 
previously (20). The expression vector 
EVA1(P67221-32) was constructed using PCR and 
infusion cloning as described (17), and has a N-
terminal 8xHis-StrepII tag. Plasmid sequences 
were confirmed by Sanger sequencing (Source 
Bioscience, UK). The CCL8 expression plasmid 
in vector pNIC-BIO3 has been described 
previously (20). 
 
Protein expression  
Evasin proteins were expressed as described 
previously using a mammalian expression system 
(20). Recombinant CCL8 was expressed as 
described previously as a SUMO fusion protein 
from Escherichia coli RosettaGamiTM 2 (DE3) 
cells (Novagen) (20). 
 
Hydrogen deuterium exchange analysis 
Working solutions of CCL8 and P672 were 
prepared at a concentration of 35 µM in 50 mM 
ammonium bicarbonate buffer pH=6.5. For 
estimation of HDX in the heterodimer state, 
solutions of CCL8 and P672 were mixed in a 
(1:1) ratio to reach a final concentration of 17.5 
µM and incubated at 4°C for 1h (20). For 
estimation of HDX in the unbound state, working 
solution were diluted to 17.5 µM with 50 mM 
ammonium bicarbonate pH=6.5. Aliquots of 4.3 
µL of heterodimer or unbound proteins were 
mixed with 48.2 µL of D2O containing 50 mM 
ammonium bicarbonate buffer adjusted to 
pH=6.5 with DCl (final content of D2O of 91.8%) 
and incubated for 5 s, 30 s, 5 min and 60 min at 
RT. HDX was quenched by adding 22.5 µL of 
10% formic acid to reach a final volume of 75 µL 
and pH=2.5, corresponding to a final 
concentration of 1 µM. Samples were then 
rapidly flash frozen in liquid nitrogen and stored 
at -80°C for up to 5 days before analysis. 
 
An Acquity M class ultra-high-performance 
liquid chromatographer with a nanoAcquity 
HDX manager coupled to a Synapt G2-Si time-
of-flight mass spectrometer (Waters) was used 
and controlled using the MassLynx 4.1 software. 
Samples were loaded at 200 µL/min into an 
Enzymate pepsin column (2.1 mm x 30 mm, 5µm 
particle size) where the proteins were quickly 
digested at 20°C. Peptides were then captured for 
2 min into a BEH C18 trap column (300 µm x 30 
mm, 1.7 µm particle size) at 0°C and then 
separated in a BEH C18 analytical column (2.1 
mm x 50 mm, 1.7 µm particle size) at 40 µL/min 
and 0°C under a 12 minutes linear gradient from 
4 to 85% of acetonitrile with 0.1% formic acid. 
The MSE approach was used for peptide mapping 
of non-deuterated proteins with trap collision 
energies of 15 to 35 V. Deuterated samples were 
analysed in scan mode only. Source parameters 
included: cone voltage 30V, capillary voltage 2.8 
KV, source temperature 80°C, desolvation 
temperature 150°C, gas cone flow rate 80 L/h and 
desolvation gas 250 L/h. 
 
The ProteinLynx Global Server 3.0.2 software 
was used for peptide mapping. Spectra were 
searched against a custom database containing 
the protein sequence of interest, requiring a non-
specific digestion enzyme and allowing for 
variable modifications (i.e. N-terminus 
pyroglutamic acid from glutamine and 
deamidation or HexNAc (N-acetylhexosamine) 
of asparagine present in a N-X-S/T motif). 
Peptide identification required at least 3 fragment 
ion matches, the peptide presence in 4 out of 5 
replicates, a retention time relative standard 
deviation of ≤ 5%, a precursor ion mass tolerance 
of 10 ppm and peptide maximum length of 30 
residues. Relative deuterium uptakes % at the 
peptide-level were estimated using Dynamix 3.0 
as the difference between the uptake (Da) 
observed for the complex species and the free 
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species divided by the maximum possible uptake 
of the peptide. Manual check of peptide retention 
time, charge state and possible peak overlap were 
also performed. Statistical analysis included a t-
Student test and HDX rate differences ≥ 5% with 
a p-value ≤ 0.05 were considered significant. 
Residues with statistically significant increased 
or decreased HDX rates (see Table S1, % 
Relative Uptake) were mapped on to a homology 
model (see below) of the P672:CCL8 complex. 
Note that in the case of overlapping peptides, 
Dynamix 3.0 displays the %Relative Uptake for 
any given residue as the %Relative Uptake of the 
shortest peptide. Additionally, in the particular 
case of overlapping peptides of equal length, the 
%Relative Uptake refers to that of the peptide in 
which the residue is closest to the peptide C-
terminus.  
 
Homology modelling 
The previously reported P672:CCL8 homology 
model (20), which was generated using the 
EVA1:CCL3 complex 3FPU (56) as template, 
was modified by replacing the CCL8 (homology 
modelled) structure with the CCL8 x-ray crystal 
structure 1ESR (28), using the align function in 
PyMol2.3.4.  
 
Biolayer Interferometry 
This was carried out as described previously 
using an OctetRed® system (17). Briefly, affinity 
determination was evaluated with chemokine 
concentrations typically ranging from 300 to 0.4 
nM, using a non-interacting reference protein to 
allow for nonspecific binding to the sensor. We 
used ForteBio Data Analysis 9 software to 
process the data and calculate association (kon), 
dissociation (koff), and affinity (Kd) constants. 
Data with poor curve fits (R2 < 0.9) were 
excluded. All biolayer interferometry 
experiments were performed at least three times.  
 
Fluorescent peptides  
All fluorescent peptides and scrambled (SCR) 
peptide were purchased from GL Biochem 
(Shanghai) and were synthesized using standard 
Fmoc solid phase synthesis to give peptides with 
a C-terminal amide. The scrambled peptide 
sequence EFTEVYEFDFKYDAPD is based on 
BK1.1. They were all deemed to be >90% pure 
by HPLC analysis and verified by LC-MS. 
Peptides were dissolved in DMSO and the 
concentration determined using NMR with TSP 
as an internal standard (57). All peptides were 
analysed using a Bruker Microflex LRF MALDI-
TOF mass spectrometer.  
 
Peptide synthesis in-house 
Amino acids were purchased from CEM. 
Peptides were purified by HPLC using a Waters 
SFO system with a Kinetex® 5 mm EVO C18 
100 Å (150 x 21.2 mm) column. All peptides 
were synthesized with a C-terminal amide on a 
0.05 mmol scale using standard Fmoc protection 
chemistry on a CEM Liberty Blue automated 
peptide synthesizer. Detailed methods are 
provided in supporting information. 
 
Fluorescence polarization assays 
Fluorescence polarization (FP) assays were 
performed using a Clariostar (BMG Tech) plate 
reader with the supplied FITC excitation and 
emission filters using 96 half area well plates 
(Corning). The buffer used (FP assay buffer) was 
50 mM HEPES, 150 mM NaCl, 0.1% BSA, 
0.002% TWEEN-20, 0.2% DMSO, pH 7.4 and 
the final volume in each well was 30 µL. 
Polarization was converted to anisotropy using 
the equation A = (2*P)/(3-P) where P is 
polarization and A is anisotropy. For each peptide 
tested the gain was set to 35mP and adjusted to a 
well containing fluorescent peptide only. The 
polarization of the emitted light in the FITC 
emission channel was then determined. 
Experiments were performed as two technical 
and three biological replicates. Screening of P672 
peptide fragments was achieved through 
incubation of each peptide (50 nM) with 1 µM 
CCL8 (Peprotech) for 30 minutes in FP assay 
buffer and the resulting anisotropy of the emitted 
light determined as above. The chemokine cross 
binding screen was performed by incubating 1 
µM chemokine (Peprotech) with 50 nM 
BK1.1FITC for half an hour in FP assay buffer and 
the resulting anisotropy of the emitted light 
determined as above. To monitor BK1.1FITC Ala 
mutants of binding to CCL8, 50 nM labelled 
peptide was incubated with varying 
concentrations of recombinant CCL8 (0-25 µM, 
final) in 30 µL FP assay buffer for 30 minutes and 
the resulting anisotropy of the emitted light 
determined as above. The anisotropy was plotted 
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as a function of CCL8 concentration and fitted to 
the equation: Y=Bmax*X/(Kd+X) + NS*X + 
Background, where Y is the measured anisotropy, 
X is the concentration of CCL8 added, Bmax is 
the maximum binding, Kd is the equilibrium 
dissociation constant, NS is the slope of the 
nonlinear regression and Background is the 
anisotropy when no CCL8 is present, in 
GraphPad Prism. Displacement assays were 
carried out with CCL7, CCL8, and CCL18 
(Peprotech, 1 µM). The chemokines were 
incubated with BK1.1 (50 µM) or SCR (50 µM) 
and BK1.1FITC (50 nM) for 30 minutes in FA 
buffer and the resulting anisotropy of the emitted 
light determined as above. For all FP assays, the 
experiments were carried out as two technical and 
three biological replicates.  
 
Native mass spectrometry analyses 
Samples were analysed using a modified Q-
Exactive mass spectrometer (Thermo Fisher 
Scientific) for high-mass range measurements 
(58). CCL8 was buffer exchanged into 200 mM 
ammonium acetate solution (pH = 6.5). BK1.1 
obtained in dimethyl sulfoxide (DMSO) was then 
added to the CCL8 homodimer solution in a 1:1 
(CCL8 monomer:BK1.1) ratio. In all cases no 
more than 0.5% DMSO was present in the final 
mixture, and a control sample of CCL8 
homodimer containing 0.5% DMSO was also 
analysed. Instrumental parameters were set to: 
capillary voltage of 1.2 KV, source temperature 
of 50°C and 60 V of source induced dissociation 
(SID). Gas phase dissociation was carried out by 
applying 35 and 55 V of higher-energy collisional 
dissociation (HCD) to the most intense charge 
state after isolation (25 m/z window). Spectra 
were acquired using a mass resolution of 60,000 
for both precursor and dissociated product ions. 
All measurements were done in triplicate.  
 
AlphaScreen assay 
AlphaScreen® Histidine detection kit was 
purchased from PerkinElmer (6760619M lot: 
2457886) and the assay was set up in white 
bottom Proxiplate™ 384 Plus microplates 
(PerkinElmer) following the manufacturer’s 
instructions. The assay buffer used was 50 mM 
HEPES, 150 mM NaCl, 0.1% BSA, 0.01% 
Tween20, 1% DMSO, pH 7.5 and the final 
volume in each well was 20 µL. Briefly, 
biotinylated chemokine (recombinant, final 
concentration 1.25 nM (CCL8, produced in-
house), 5 nM (CCL2, Almac) and 2.5 nM (CCL3, 
Almac) was pre-incubated at room temperature 
for 15 min with different concentrations of each 
peptide. His-tagged P672 (final concentration 2. 
5 nM (CCL8), 5 nM (CCL2) and 1.25 nM 
(CCL3)) was then added to each well and the 
plate was incubated at room temperature for 30 
min. Finally, acceptor and donor beads were 
added as a 1:1 suspension in buffer to each well 
and the plate was further incubated at RT for 1h. 
Data was obtained by reading the plate using a 
Pherastar FSX plate reader (excitation 680nm, 
emission 570nm) and was analysed using 
GraphPad Prism.  
 
Isothermal calorimetry 
Experiments were carried out on a TA 
Instruments Affinity ITC with low volume cells 
at 25°C and stirring at 250 rpm using a buffer 
system of HEPES 50 mM, NaCl 150 mM, pH 7.5. 
Twenty sequential 2 µL injections of BK1.3 (125 
µM) into CCL8 (10 µM) were used to generate a 
binding isotherm for the interaction which was 
fitted to the independent (single-site) model using 
NanoAnalyze (v3.11.0). 
 
Fluorescent chemokine/receptor blocking assay 
CCL8-647 (2.5 nM, final) or CCL2-657 (1.2 nM, 
final) was incubated for 30 minutes with varying 
doses of peptide (0-100 µM, final concentration) 
in 50 µL assay buffer (RPMI-1640 + L-glutamine 
(4 mM) + 10% heat treated fetal bovine serum + 
0.2% DMSO) at 37°C. This mixture was then 
added to 50,000 THP-1 cells in a 96-well v-
bottomed plated to give a final volume of 100 µL, 
and everything incubated together for a further 30 
minutes at 37°C. Following this time, the plate 
was centrifuged, the supernatant flicked off, and 
the cells resuspended in 150 µL ice cold PBSA. 
This was repeated twice more and the cells were 
finally resuspended in 150 µL ice cold PBSA. 
The median fluorescence intensity of 10,000 cells 
on the RL-1 channel was determined using an 
ATTUNE flow cytometer and plotted as function 
of peptide concentration and the data fitted to an 
inhibitor response curve with 4 parameters using 
GraphPad Prism. Experiments were performed as 
two technical and three biological replicates. 
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THP-1 cell migration assays 
THP-1 monocyte cell migration assays were 
carried out as described (17). IC50 was calculated 
by fitting an inhibitor response curve with 4 
parameters in GraphPad Prism. Experiments 
were performed as 3 technical and 3 biological 
replicates. 
 
Subcutaneous dorsal air pouch model 
C57BL/6J male mice (25-30 g, 8-10-week-old) 
were obtained from Charles River (UK). Air 
pouches were established at the dorsal side of the 
mice as described (59). Detailed methods are 
provided in supporting information. All animal 
procedures were approved by the UK Home 
Office and carried out in accordance with the UK 
Animals (Scientific Procedures) Act 1986, under 
project license PPL P973A60F5. 
 
Statistical Analysis  
All statistical analyses were performed using 
GraphPad Prism 8. The statistical significance 
was evaluated by one-way analysis of variance 
(ANOVA). P value (probability of a type I error) 
was adjusted for multiple comparisons with 
threshold (alpha) for a type I error <0.05. Unless 
otherwise indicated all data are represented as the 
mean ± s.e.m. of three independent experiments. 
 
Data availability 
Mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium 
via PRIDE (55) with the dataset identifier 
PXD019199. Reviewer account details are: 
Username reviewer15555@ebi.ac.uk, Password: 
10jcfQze. All other data are contained within the 
manuscript or in supporting information. 
Plasmids and sequences are available on request 
from SB (sbhattac@well.ox.ac.uk).  
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Figures and Legends 
 
Figure 1. Characterization of CCL8/P672 interface by HDX-MS. A, Surface representation (top) and 
ribbon diagram (bottom) of a homology model of P672 (purple) and CCL8 (green) complex (see methods 
for details of model generation). P672 and CCL8 in 1:1 ratio was pre-incubated for 1h, then diluted in D2O 
containing buffer and quenched at different time intervals (5s, 30s, 5min, 60min). B, Surface representation 
(top) and ribbon diagram (bottom) of P672 and CCL8 complex at the time points indicated. Residues with 
statistically significant increased HDX rates, (exposed residues, see Table S1) are shown in blue. Regions 
with statistically significant decreased HDX rates (protected residues, see Table S1) are shown in purple 
for P672 and in green for CCL8. All analyses were performed in triplicate. C, Surface representations (top) 
and ribbon diagrams (bottom) of P672 (-90° rotated view along the y-axis of B). Residues protected at 5s 
and 30s time points (E22-F32) are indicated in purple. Exposed residues (G87-C94) are indicated in blue. 
The surface of the protected residues (E22-F32) is also shown in the bottom panel. D, Surface representation 
(top) and ribbon diagram (bottom) of CCL8, with residues protected at all time points (R18-S27) indicated 
in green. Disulfide bonds are indicated in yellow. The surface of the N-loop (residues C12-R24) is also 
shown in the bottom panel to show the overlap with protected residues. E, Spectra of two representative 
peptides from the Y21-F32 region in P672 (green and black bars) that are protected from deuterium uptake 
upon complex formation. H/D exchange mass spectra were measured at t = 5s. These peptides display 
reduced relative deuterium uptake upon complex formation. Other peptides from this region are indicated 
as grey bars. Mass spectra are shown for control non-deuterated peptides (E-i, iv), unbound P672 deuterated 
peptides (E-ii, v), and P672 deuterated peptides when in complex with CCL8 (E-iii, vi).  
 
  
A B C D
E
90°
90°
Non-deuterated
Unbound (-CCL8)
Complex (+CCL8)
Non-deuterated
Unbound (-CCL8)
Complex (+CCL8)
i
ii
iii
iv
v
vi
P672 Y21-F32
identified peptides
Y E D F F K P V T C Y F
CCL8
P672
CCL8
5s – 1h
P672
5s, 30s
CCL8
P672
CCL8
5s – 1h
P672
5s, 30s
P76
W104
P672
5s, 30s
E22-F32
G87-C94
V1
P2
P76
CCL8
5s - 1h
R18-S27
Evasin-inspired peptides 
 
 17 
 
Figure 2. Design and biophysical analysis of an EVA1/P672 hybrid protein. A, Alignment of EVA1, 
P672 and EVA1/P672 (EVA1 containing P672E22-E32) hybrid protein using MUSCLE algorithm. Amino 
acids are color-coded according to physicochemical properties: yellow, aromatic (F, W, and Y); red, acidic 
(D and E); blue, basic (R, H, and K); orange, nonpolar aliphatic (A, G, I, L, M, P, and V); green, polar 
neutral (C, N, Q, and T). Amino acids that were protected from deuterium uptake in P672 are indicated 
with a red box. The N-terminal acidic region is enclosed in a black box. B, Biolayer interferometry 
sensorgram obtained when either P672, EVA1/P672 or EVA1 is loaded onto the BLI sensor and exposed 
to 600 nM CCL8. Plots display wavelength shift (Y-axis, nm) versus time (X axis, seconds). C, Biolayer 
interferometry sensorgram for EVA1/P672 hybrid binding to CCL8. Dotted lines indicate collected data, 
solid lines indicate modelled data. Plots display wavelength shift (Y-axis, nm) versus time (X axis, 
seconds). 
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Figure 3. Development and biophysical analysis of P672-derived peptides. A, Design of a P672 peptide 
tiling array to identify CCL8-binding peptides. Positions of each residue within P672 are indicated, and the 
grey box indicates the CCL8 binding region identified by HDX-MS. P672 residues are colored according 
to CCL8 binding affinity from the Ala-scanning mutagenesis (see text and below). Red indicates either 
complete or highly significant loss of activity (P<0.0001), blue indicates moderately significant loss of 
activity (P<0.05). Peptides synthesized (BK1.1 – BK6) are indicated as grey bars. B, Fluorescent peptides 
BK1.1 – BK6 (50 nM) were incubated with CCL8 (1 µM) and the resulting anisotropy determined. A 
scrambled peptide (S, SCRFITC) was used as a negative control. The anisotropy of each peptide after being 
incubated with CCL8 was compared to scrambled peptide using one-way ANOVA with Sidak’s correction 
for multiple comparisons. **** indicates P ≤ 0.0001. C, Fluorescent polarization assay to determine 
binding of BK1.1FITC to CCL8. The Y axis shows anisotropy, and X axis the dose of CCL8. Individual data 
points are indicated for one dataset. The curve was fitted as described in methods to calculate Kd. The mean 
Kd and s.e.m. of three independent experiments is shown. D, Fluorescent polarization assay to assess effect 
of alanine-scanning mutagenesis of BK1.1FITC on CCL8 binding. Kd values for each BK1.1FITC Ala mutant 
are shown as mean ± s.e.m of three biological replicates, which are individually indicated as points. Data 
for each mutant was compared to wild-type (WT) BK1.1, using a one-way ANOVA with Sidak’s correction 
for multiple comparisons. **** = P ≤ 0.0001, * = P≤ 0.05. The mutant P27A showed no detectable binding. 
E, Mass spectrometry (MS) to assess effect of BK1.1 on CCL8 Top panel: Native MS of CCL8 homodimer. 
Mid panel: In-solution dissociation of CCL8 dimer and further binding of CCL8 to one and two BK-1. 
Confirmation of CCL8/BK-1 complex by HCD gas-phase dissociation of isolated precursor ions: Bottom 
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panel, left: 2217 m/z corresponding to CCL8/BK1.1 (1:1) and Bottom panel, left: 2555 m/z corresponding 
to CCL8/BK1.1 (1:2). Buffers contained up to 0.5% DMSO. All analyses were performed in triplicate. 
F, Fluorescent polarization assay to assess the binding of BK1.1FITC against a CC-chemokine panel. Data 
are presented as mean ± s.e.m of three biological replicates, which are individually indicated as points. Each 
biological replicate was performed as technical duplicate. CXCL1 was used as a negative control. CC-
chemokine binding compared to the negative control using a one-way ANOVA with Sidak’s correction for 
multiple comparisons. **** = P ≤ 0.0001, * P<0.05. G-I, Fluorescence polarization competition assay for 
BK1.1FITC and CC-chemokine interactions. BK1.1FITC (50 nM) was incubated with the indicated chemokine 
(1 µM) with or without unlabeled BK1.1 or SCR (BK1.1 scrambled) peptides (50 µM) for 30 min and the 
resulting anisotropy was measured. Data are presented as mean ± s.e.m of three biological replicates, which 
are individually indicated as points. Each biological replicate was performed as technical duplicate. 
Statistical significance of differences (SCR versus BK1.1) were calculated using a one-way ANOVA. 
**** = P ≤ 0.0001, *** = P ≤ 0.001.  
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Figure 4. Development and biophysical analysis of the BK1.1 peptide series. A, Sequences of peptides 
studied, with disulfide bond (BK1.3) or thioether cyclization (BK1.2, BK1.4) indicated by lines. SCR is a 
scrambled peptide based on the sequence of BK1.1. B-D, Effect of indicated peptides at a concentration of 
100 µM on a His-tagged P672 – biotinylated CCL8, CCL2 or CCL3 interaction respectively using an 
AlphaScreen assay. In each panel. Y axis shows intensity counts, and X axis the peptide. Data are presented 
as mean ± s.e.m. of three independent experiments, shown as individual data points. Statistically 
significant differences (compared to chemokine + P672), using a one-way ANOVA with Sidak’s multiple 
comparisons test are indicated by asterisks. **** =P ≤ 0.0001, *** =P ≤ 0.001, **= P ≤ 0.01. E, G, I, 
Representative dose-response AlphaScreen assay curves showing disruption of His-tagged P672 
interactions with biotinylated human CCL8, CCL2 and CCL3 respectively by each member of the BK1.1 
derived series. Y axis shows intensity counts, and X axis the peptide concentration (Log10 Molar). Data are 
shown as mean of two technical replicates. Curves were fitted with 4 parameters to estimate IC50. F, H, 
J, Summary IC50 values for inhibition of His-tagged P672 binding to human CCL8, CCL2 and CCL3 
respectively by each member of the BK1.1 derived series, where these could be calculated. Y axis shows 
IC50 (M). Data are presented as mean ± s.e.m. of three independent experiments, each shown as individual 
data points. Each independent experiment was conducted as two technical replicates. Summary IC50 
values and Hill slopes are provided in Table S3. Statistically significant differences (compared to BK1.1), 
using a one-way ANOVA with Sidak’s multiple comparisons test, are indicated by black asterisks. 
Statistically significant differences (pairwise comparisons of BK1.2, BK1.3, BK1.4 and BK1.5) using 
one-way ANOVA with Tukey’s multiple comparisons test are indicated with blue asterisks (comparisons 
to BK1.2), or green asterisks (comparisons to BK1.3). *** =P ≤ 0.001, **= P ≤ 0.01, *= P ≤ 0.05. K, 
Isothermal calorimetry measurements of BK1.3 binding to CCL8. Y axis shows the thermal power applied 
during sequential injections of BK1.3 to maintain constant temperature, and X-axis shows the time. L. 
Binding isotherm of BK1.3 binding to CCL8. Each point represents a single injection. Binding enthalpy 
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(kJ/mol) is shown on the Y axis, and molar ratio of BK1.3 to CCL8 on the X axis. An independent single 
site model (green line) was fitted to the data. Calculated thermodynamic binding parameters (± 95% 
confidence interval) are Kd = 217 ± 83 nM, stoichiometry n = 0.776 ± 0.024, enthalpy DH= -28.12 ± 1.587 
kJ/mol, and entropy DS = 33.26 J/mol/K. Values for the blank model were 0.309 ± 0.109 µJ. 
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Figure 5. Cell-based assessment of P672-derived peptide activity. A-D, Inhibition of human chemokine 
induced THP-1 cell migration by BK1.1, BK1.2, BK1.3, SCR (BK1.1 scrambled, negative control) 
peptides, each at 10µM, and by P672 protein (positive control, 300 nM). Y axis in each panel shows % 
migration of THP-1 cells normalized to chemokine alone which was set at 100%. All experiments were 
performed at EC80 doses of CCL8 (5.8 nM), CCL7 (7.2 nM), CCL3 (3.5 nM), and CCL2 (1.2 nM), 
respectively. Data are shown as mean ± s.e.m. of three independent biological replicates, shown as 
individual data points. Each biological experiment was performed as three technical replicates. 
Statistically significant differences (compared to SCR), using a one-way ANOVA with Sidak’s correction 
for multiple comparisons, are indicated by asterisks: **** = P ≤ 0.0001, *** =P ≤ 0.001, **= P ≤ 0.01, *= 
P ≤ 0.05. E, Representative dose-response curves showing inhibition of human CCL8 induced THP-1 cell 
migration by BK1.1 (black), BK1.2 (blue), BK1.3 (green), SCR (scrambled, negative control, grey) 
peptides and by P672 protein (positive control, magenta). Y axis shows % migration of THP-1 cells 
normalized to CCL8 alone which was set at 100%. Data are shown as mean ± s.e.m. of three technical 
replicates. X-axis shows inhibitor concentration (Log10 Molar). Curves were fitted with 4 parameters to 
estimate IC50.  F, Summary IC50 values for inhibition of human CCL8 induced THP-1 cell migration by 
BK1.1, BK1.2, BK1.3, and P672 protein. Y axis shows IC50 (M). Data are shown as mean ± s.e.m. of three 
biological replicates. Summary IC50 values and Hill slopes are provided in Table S3. Statistically 
significant differences (compared to BK1.1) using a one-way ANOVA with Sidak’s correction for 
multiple comparisons, are indicated by asterisks: **** = P ≤ 0.0001, *** =P ≤ 0.001, **= P ≤ 0.01, *= P 
≤ 0.05. G, I, Representative dose-response curves showing inhibition of human CCL8-647 (G) and human 
CCL2-647 (I) induced THP-1 cell fluorescence by BK1.1 (black), BK1.2 (blue), BK1.3 (green), SCR 
(scrambled, negative control, grey) peptides and by P672 protein (positive control, magenta). Y axis shows 
fluorescence (arbitrary units). Data are shown as mean of two technical replicates. X axis shows 
inhibitor concentration (Log10 Molar). Curves were fitted with 4 parameters to estimate IC50. H, J, 
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Summary IC50 values for inhibition of human CCL8-647 (H) or CCL2-647 (I) induced THP-1 cell 
fluorescence by BK1.1, BK1.2, BK1.3, and P672 protein. Y axis shows IC50 (M). Data are shown as mean 
± s.e.m. of three biological replicates, shown as individual data points. Each biological experiment was 
conducted as two technical replicates. Statistically significant differences (compared to BK1.1) using a 
one-way ANOVA with Sidak’s correction for multiple comparisons, are indicated by asterisks: **** = P 
≤ 0.0001, *** =P ≤ 0.001, **= P ≤ 0.01, *= P ≤ 0.05. 
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Figure 6. Assessment of anti-inflammatory activity of locally or systemically administered peptide in 
a mouse dorsal air-pouch model. A, Experimental design to assess efficacy of locally administered 
peptide. A dorsal air-pouch (a.p.) was created by subcutaneous (s.c.) injection of air on day 0 and day 3. 
Zymosan (red) or PBS (control) was injected into the air-pouch (a.p.) on day 6. Peptide or protein (blue) 
was injected into the air-pouch on day 6 at the time of zymosan injection and repeated 9 hours later. Air-
pouch exudate was collected and analysed on day 7 by flow cytometry (FC). Nine mice were studied in 
each of 5 study arms: PBS alone (PBS), zymosan (zymo), zymosan + scrambled peptide (SCR), zymosan 
+ P672 (P672), and zymosan + BK1.3 (BK1.3). B-F, Summary data for flow cytometry analysis for locally 
administered peptide. Y axis shows cell counts of total leucocytes (B), neutrophils (C), eosinophils (D), 
monocytes (E) and T-cells (F). Data are presented for each arm as mean ± s.e.m. and with individual data 
points. Statistically significant differences (compared to zymosan) using a one-way ANOVA with 
Dunnett’s correction for multiple comparisons, are indicated by asterisks: **** = P ≤ 0.0001, *** =P ≤ 
0.001, **= P ≤ 0.01, *= P ≤ 0.05. G, Experimental design to assess efficacy of intraperitoneally administered 
peptide. This is identical to that used for locally administered peptide (above) except that peptide or protein 
was administered intra-peritoneally (i.p.). Nine mice were studied in each of 3 study arms: zymosan + SCR, 
zymosan + P672 (P672), and zymosan + BK1.3 (BK1.3). H-I, Summary data for flow cytometry analysis 
for intraperitoneally administered peptide. Y axis shows cell counts of total leucocytes (H), neutrophils (I), 
eosinophils (J), monocytes (K) and T-cells (L). Data are presented for each arm as mean ± s.e.m. and with 
individual data points. Statistically significant differences (compared to SCR) using a one-way ANOVA 
with Dunnett’s correction for multiple comparisons, are indicated by asterisks: **** = P ≤ 0.0001, *** =P 
≤ 0.001, **= P ≤ 0.01, *= P ≤ 0.05. 
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